People and Business News — 10/21
People news
Kimberly Tableman joined Castor as Chief Clinical Development Officer and Anna Wozniak as Chief Financial & Development Officer.
AiCure has added the following new senior team members: Brian Jung as Chief Financial Officer; Lynne Rowlandas Chief Marketing Officer, Aaron Masino, PhD, as Senior Director of Digital Biomarker Development; Nina Tayloras Director, Strategic Partnerships; and Viren Kavia as Director, Strategic Partnerships.
Curavit Clinical Research announced the appointments of Jay Collier, as Chief Operating Officer, and Candice Del Rio, as Director of Clinical Operations.
uMotif announced Steve Rosenberg was appointed to CEO.
Worldwide Clinical Trials announced the appointment of Dr. Wolfram C.M. Dempke, as Vice President, Scientific Solutions, Hematology & Oncology.
Parexel announced the appointment of Stephen Pyke as the company’s Executive Vice President, Clinical Data and Digital Services.
Medable Inc. announced the hiring of Orlando Baeza as the company’s first chief marketing officer.
Anju Software hired a new Vice President of Operations, Michael Keens.
Business news
Futura Medical is partnering with OCT Clinical to run its FM71 study in Eastern Europe and the USA.
Remarque Systems’ platform is the industry’s first patented trail-audited real-time risk-based quality management system.
Recognition
PHASTAR was announced as a joint winner of the 2021 Innovation in the Management of Clinical Data Award by the Association for Clinical Data Management.
Anju Software has been named by Gartner as a sample vendor in four categories in its 2021 Hype Cycle Life Sciences Research and Development report and Commercial Operations report.
Elligo Health Research was named winner of the 2021 Site Tank Award at Society for Clinical Research Site’s recent 2021 Global Site Solutions Summit for their virtual AI-powered clinical trial engagement assistant, Root.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
